Clinical Edge Journal Scan

Fevers following radiofrequency ablation for HCC strike soon after procedure


 

Key clinical point: Fever following radiofrequency ablation in hepatocellular carcinoma patients was independently associated with younger age, low serum albumin level, general anesthesia, tumor size, and tumor number.

Major finding: The adjusted odds ratios for the independent predictors of fever in these patients were 0.96 for younger age, 0.49 for low serum albumin level, 2.06 for general anesthesia, 1.52 for tumor size, and 1.71 for tumor number. HCC patients who developed fevers after radiofrequency ablation also had significantly longer hospital stays than those without fevers (9.06 days vs 5.50 days).

Study details : The data come from a retrospective study of 272 adults with new or recurrent hepatocellular carcinoma who underwent ultrasonography-guided radiofrequency ablation (RFA) between April 2014 and February 2019.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen P-Y et al. Cancers (Basel). 2021 Oct 22. doi: 10.3390/cancers13215303.

Recommended Reading

Liver imaging algorithm predicts success of SBRT in hepatocellular carcinoma
Federal Practitioner
Liver imaging algorithm predicts success of SBRT in hepatocellular carcinoma
Federal Practitioner
Repeat hepatic resection extends recurrence-free survival in recurrent HCC
Federal Practitioner
Nucleotide analog treatment shows promise in hepatitis B-related HCC
Federal Practitioner
TACE combination therapy improved outcomes in intermediate and advanced HCC
Federal Practitioner
Lipiodol retention patterns show no impact on overall survival in HCC
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC November 2021
Federal Practitioner
Laparoscopic liver resection yields better outcomes after HCC
Federal Practitioner
Selective internal radiation therapy (SIRT) triggers late liver decompensation in HCC
Federal Practitioner
AI analysis predicts post-surgery recurrence of hepatocellular carcinoma
Federal Practitioner